How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise
Quick Take
Pfizer aims to surpass its $6 billion franchise through innovative strategies and new drug developments.
Key Points
- Focus on expanding existing drug portfolios.
- Invest in cutting-edge research and development.
- Leverage partnerships for market growth.
📖 Reader Mode
~1 min read
The next-generation version of Pfizer's (PFE) $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study, the S&P 500 drug giant said Wednesday. Pfizer compared four doses of its new vaccine in infants to four doses of Prevnar 20 at months two, four, six and 12-15. Prevnar 20, as the name suggests, blocks 20 strains of a bacteria…
Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Related news
Why Pfizer's 'Mild' First-Quarter Report Likely Won't Satisfy Skeptics
5/05/2026 Pfizer's "mild" first-quarter report is unlikely to satisfy skeptics, an expert said Tuesday. But Pfizer stock recovered and closed higher.
5/05/2026 Pfizer's "mild" first-quarter report is unlikely to satisfy skeptics, an...
— Originally published at investors.com
More from Yahoo Finance
See more →
These Super Stocks Could Be the Biggest Winners in the AI Inference and Agentic AI Economy
The article highlights top stocks poised for growth in the AI inference and agentic AI sectors.
